Disputed <i>rpoB</i> Mutations in Mycobacterium tuberculosis and Tuberculosis Treatment Outcomes
Wan-Hsuan Lin, Wei-Ting Lee, Hsing-Yuan Tsai, Ruwen Jou
Abstract
Discordant results between genotypic drug susceptibility testing (gDST) and phenotypic DST (pDST) for Mycobacterium tuberculosis isolates with disputed mutations affect rifampin (RIF)-resistant (RR) and multidrug-resistant (MDR) tuberculosis (TB) treatments due to a lack of practical clinical guidelines. To investigate the role of disputed rpoB mutations in M. tuberculosis and TB treatment outcomes, initial isolates of 837 clinical RR- or MDR-TB cases confirmed during 2014 to 2018 were retested using agar-based RIF pDST and rpoB gene sequencing.
Topics & Concepts
rpoBRifabutinMycobacterium tuberculosisTuberculosisBiologyMicrobiologyRifampicinGenotypeDrug resistanceMedicineVirologyAntibioticsGeneticsClarithromycinGenePathologyTuberculosis Research and EpidemiologyMycobacterium research and diagnosisCancer therapeutics and mechanisms